Corcept Therapeutics (CORT), which announced it received from the FDA a complete response letter regarding the new drug application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism, is set to resume trading at 8:20 am ET, with quotation scheduled to resume at 8:15 am ET.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT: